Changes and Influential Factors of Chemotherapy Usage for Non-Small Cell Lung Cancer Patients in China: A Multicenter 10-Year (2005-2014) Retrospective Study.
adjuvant chemotherapy
chemotherapy
epidemiology
neo-adjuvant chemotherapy
non-small cell lung cancer
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
03
2020
accepted:
09
06
2020
entrez:
9
8
2020
pubmed:
9
8
2020
medline:
9
8
2020
Statut:
epublish
Résumé
Chemotherapy has improved the survival of non-small cell lung cancer (NSCLC) patients over the past few decades. However, there have not been any epidemiological studies on chemotherapy for Chinese NSCLC patients. The patients diagnosed as primary lung cancer between January 1, 2005, and December 31, 2014, in eight hospitals from eight provinces in China were retrospectively reviewed. Demographic and clinical data were extracted from medical history systems. Chi-square test and logistic regression were used to analyze the changes of chemotherapy usage and influential factors. A total of 7184 lung cancer cases were eligible, among which 6481 NSCLC cases were included in this analysis. Among stage I/II patients, the percentages of receiving adjuvant chemotherapy did not change significantly between the earlier (28.5%) and the latter five years (25.7%) ( From 2005 to 2014, there was no significant change in the chemotherapy pattern of early NSCLC. Economic factors mainly contributed to the significant changes in the first-line chemotherapy regimen selection for advanced patients.
Sections du résumé
BACKGROUND
BACKGROUND
Chemotherapy has improved the survival of non-small cell lung cancer (NSCLC) patients over the past few decades. However, there have not been any epidemiological studies on chemotherapy for Chinese NSCLC patients.
PATIENTS AND METHODS
METHODS
The patients diagnosed as primary lung cancer between January 1, 2005, and December 31, 2014, in eight hospitals from eight provinces in China were retrospectively reviewed. Demographic and clinical data were extracted from medical history systems. Chi-square test and logistic regression were used to analyze the changes of chemotherapy usage and influential factors.
RESULTS
RESULTS
A total of 7184 lung cancer cases were eligible, among which 6481 NSCLC cases were included in this analysis. Among stage I/II patients, the percentages of receiving adjuvant chemotherapy did not change significantly between the earlier (28.5%) and the latter five years (25.7%) (
CONCLUSION
CONCLUSIONS
From 2005 to 2014, there was no significant change in the chemotherapy pattern of early NSCLC. Economic factors mainly contributed to the significant changes in the first-line chemotherapy regimen selection for advanced patients.
Identifiants
pubmed: 32765102
doi: 10.2147/CMAR.S253789
pii: 253789
pmc: PMC7381789
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6033-6044Informations de copyright
© 2020 Xing et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest with respect to this research study and paper.
Références
J Thorac Oncol. 2010 Apr;5(4):510-6
pubmed: 20107424
BMJ. 2011 Jul 14;343:d4013
pubmed: 21757436
Health Technol Assess. 2013 Jul;17(31):1-278
pubmed: 23886301
Lung Cancer. 2019 Feb;128:91-100
pubmed: 30642458
J Thorac Dis. 2016 Oct;8(10):2832-2842
pubmed: 27867559
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
N Engl J Med. 2002 Jan 10;346(2):92-8
pubmed: 11784875
Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):243-50
pubmed: 15668501
Lung Cancer. 2006 Jan;51(1):105-14
pubmed: 16310886
Br J Cancer. 2007 Mar 26;96(6):886-90
pubmed: 17342091
J Natl Cancer Inst. 1994 May 4;86(9):673-80
pubmed: 8158698
J Clin Oncol. 2010 Jan 1;28(1):35-42
pubmed: 19933916
J Natl Compr Canc Netw. 2017 Apr;15(4):504-535
pubmed: 28404761
Br J Cancer. 2004 Jan 26;90(2):359-65
pubmed: 14735177
J Clin Oncol. 2003 Nov 1;21(21):3909-17
pubmed: 14581415
Adv Exp Med Biol. 2016;893:1-19
pubmed: 26667336
Asian Pac J Cancer Prev. 2010;11(6):1587-94
pubmed: 21338201
Lung Cancer. 2007 Jun;56(3):363-9
pubmed: 17306906
J Natl Compr Canc Netw. 2012 May;10(5):599-613
pubmed: 22570291
J Clin Oncol. 1988 Apr;6(4):633-41
pubmed: 2833577
Cancer Med. 2017 Oct;6(10):2440-2452
pubmed: 28941012
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
J Clin Oncol. 2008 Jul 20;26(21):3543-51
pubmed: 18506025
Lung Cancer. 2009 Feb;63(2):264-70
pubmed: 18649969
J Clin Oncol. 2002 Nov 1;20(21):4285-91
pubmed: 12409326
Lung Cancer. 2017 Jan;103:66-74
pubmed: 28024699
Chest. 2013 May;143(5 Suppl):e278S-e313S
pubmed: 23649443
N Engl J Med. 2004 Jan 22;350(4):351-60
pubmed: 14736927
Eur J Cancer. 2005 Jan;41(1):81-92
pubmed: 15617993
BMJ. 1995 Oct 7;311(7010):899-909
pubmed: 7580546
Lancet Oncol. 2006 Sep;7(9):719-27
pubmed: 16945766
Cancer. 2009 May 15;115(10):2199-211
pubmed: 19365824
Oncologist. 2009 Sep;14(9):930-5
pubmed: 19737998